Top

Journal of Cardiovascular Translational Research

Published in:

01-12-2009

Mechanical and Energetic Consequences of HCM-Causing Mutations

Authors: Cecilia Ferrantini, Alexandra Belus, Nicoletta Piroddi, Beatrice Scellini, Chiara Tesi, Corrado Poggesi

Published in: Journal of Cardiovascular Translational Research | Issue 4/2009

Abstract

Hypertrophic cardiomyopathy (HCM) was the first inherited heart disease to be characterized at the molecular genetic level with the demonstration that it is caused by mutations in genes that encode different components of the cardiac sarcomere. Early functional in vitro studies have concluded that HCM mutations cause a loss of sarcomere mechanical function. Hypertrophy would then follow as a compensatory mechanism to raise the work and power output of the affected heart. More recent in vitro and mouse model studies have suggested that HCM mutations enhance contractile function and myofilament Ca²⁺ sensitivity and impair cardiac myocyte energetics. It has been hypothesized that these changes may result in cardiac myocyte energy depletion due to inefficient ATP utilization and also in altered myoplasmic Ca²⁺ handling. The problems encountered in reaching a definitive answer on the effects of HCM mutations are discussed. Though direct analysis of the altered functional characteristics of HCM human cardiac sarcomeres has so far lagged behind the in vitro and mouse studies, recent work with mechanically isolated skinned myocytes and myofibrils from affected human hearts seem to support the energy depletion hypothesis. If further validated in the human heart, this hypothesis would identify tractable therapeutic targets that suggest that HCM, perhaps more than any other cardiomyopathy, will be amenable to disease-modifying therapy.

Arad, M., Benson, D. W., Perez-Atayde, A. R., McKenna, W. J., Sparks, E. A., Kanter, R. J., et al. (2002). Constitutively active AMP kinase mutations cause glycogen storage disease mimicking hypertrophic cardiomyopathy. J Clin Invest, 109, 357–362.PubMed

Ashrafian, H., Redwood, C., Blair, E., & Watkins, H. (2003). Hypertrophic cardiomyopathy: a paradigm for myocardial energy depletion. Trends in Genetics, 19, 263–268.CrossRefPubMed

Ashrafian, H., & Watkins, H. (2007). Reviews of translational medicine and genomics in cardiovascular disease: new disease taxonomy and therapeutic implications. J Am Coll Cardiol, 49, 1251–1264.CrossRefPubMed

Baudenbacher, F., Schober, T., Pinto, J. R., Sidorov, V. Y., Hilliard, F., Solaro, R. J., et al. (2008). Myofilament Ca²⁺ sensitization causes susceptibility to cardiac arrhythmia in mice. J Clin Invest, 118, 3893–3903.PubMed

Bing, W., Knott, A., Redwood, C., Esposito, G., Purcell, I., Watkins, H., et al. (2000). Effect of hypertrophic cardiomyopathy mutations in human cardiac muscle alpha-tropomyosin (Asp175Asn and Glu180Gly) on the regulatory properties of human cardiac troponin determined by in vitro motility assay. J Mol Cel Cardiol, 32, 1489–1498.CrossRef

Blair, E., Redwood, C., Ashrafian, H., Oliveira, M., Broxholme, J., Kerr, B., et al. (2001). Mutations in the gamma(2) subunit of AMP-activated protein kinase cause familial hypertrophic cardiomyopathy: evidence for the central role of energy compromise in disease pathogenesis. Human molecular genetics, 10, 1215–1220.CrossRefPubMed

Belus, A., Piroddi, N., Scellini, B., Tesi, C., D’Amati, G., Girolami, F., et al. (2008). The FHC-associated myosin mutation R403Q accelerates tension generation and relaxation of human cardiac myofibrils. J Physiol, 586, 3639–3644.PubMed

Bonne, G., Carrier, L., Bercovici, J., Cruaud, C., Richard, P., Hainque, B., et al. (1995). Cardiac myosin binding protein-C gene splice acceptor site mutation is associated with familial hypertrophic cardiomyopathy. Nat Genet, 11, 438–440.CrossRefPubMed

Borbély, A., van der Velden, J., Bronzwaer, J. G. F., Papp, Z., Édes, I., Stienen, G. J. M., et al. (2005). Cardiomyocyte stiffness in diastolic heart failure. Circulation, 111, 774–781.CrossRefPubMed

10.

Bottinelli, R., Coviello, D. A., Redwood, C. S., Pellegrino, M. A., Maron, B. J., Spirito, P., et al. (1998). A mutant tropomyosin that causes hypertrophic cardiomyopathy is expressed in vivo and associated with an increased calcium sensitivity. Circ Res, 82, 106–115.PubMed

11.

Crilley, J. G., Boehm, E. A., Blair, E., Rajagopalan, B., Blamire, A. M., Styles, P., et al. (2003). Hypertrophic cardiomyopathy due to sarcomeric gene mutations is characterized by impaired energy metabolism irrespective of the degree of hypertrophy. J Am Coll Cardiol, 41, 1776–1782.CrossRefPubMed

12.

Cuda, G., Fananapazir, L., Zhu, W. S., Sellers, J. R., & Epstein, N. D. (1993). Skeletal muscle expression and abnormal function of beta-myosin in hypertrophic cardiomyopathy. J Clin Invest, 91, 2861–2865.CrossRefPubMed

13.

Dyer, E., Jacques, A., Burch, M., Kaski, J. P., & Marston, S. (2008). Functional effects of DCM mutation G159D in troponin C from an explanted heart. J Mol Cell Cardiol, 44, 729–730.CrossRef

14.

Elliott, K., Watkins, H., & Redwood, C. S. (2000). Altered regulatory properties of human cardiac troponin I mutants that cause hypertrophic cardiomyopathy. J Biol Chem, 275, 22069–22074.CrossRefPubMed

15.

Fujita, H., Sugiura, S., Momomura, S., Omata, M., Sugi, H., & Sutoh, K. (1997). Characterization of mutant myosins of Dictyostelium discoideum equivalent to human familial hypertrophic cardiomyopathy mutants. Molecular force level of mutant myosins may have a prognostic implication. J Clin Invest, 99, 1010–1015.CrossRefPubMed

16.

Geisterfer-Lowrance, A. A., Christe, M., Conner, D. A., Ingwall, J. S., Schoen, F. J., Seidman, C. E., et al. (1996). A mouse model of familial hypertrophic cardiomyopathy. Science, 272, 731–734.CrossRefPubMed

17.

Geisterfer-Lowrance, A. A., Kass, S., Tanigawa, G., Vosberg, H. P., McKenna, W., Seidman, C. E., et al. (1990). A molecular basis for familial hypertrophic cardiomyopathy: a beta cardiac myosin heavy chain gene missense mutation. Cell, 62, 999–1006.CrossRefPubMed

18.

Hajjar, R. J., Gwathmey, J. K., Briggs, G. M., & Morgan, J. P. (1988). Differential effect of DPI 201–106 on the sensitivity of the myofilaments to Ca2+ in intact and skinned trabeculae from control and myopathic human hearts. J Clin Invest, 82, 1578–1584.CrossRefPubMed

19.

He, H., Javadpour, M. M., Latif, F., Tardiff, J. C., & Ingwall, J. S. (2007). R-92L and R-92W mutations in cardiac troponin T lead to distinct energetic phenotypes in intact mouse hearts. Biophys J, 93, 1834–1844.CrossRefPubMed

20.

Ho, C., Sweitzer, N. K., McDonough, B., Maron, B. J., Casey, S. A., Seidman, J. G., et al. (2002). Assessment of diastolic function with doppler tissue imaging to predict genotype in preclinical hypertrophic cardiomyopathy. Circulation, 105, 2992–2997.CrossRefPubMed

21.

Hoffmann, B., Schmidt-Traub, H., Perrot, A., Osterziel, K. J., & Gessner, R. (2001). First mutation in cardiac troponin C, L29Q, in a patient with hypertrophic cardiomyopathy. Hum Mutat, 17, 524.CrossRefPubMed

22.

Hofmann, P. A., Hartzell, H. C., & Moss, R. L. (1991). Alterations in Ca2+ sensitive tension due to partial extraction of C-protein from rat skinned cardiac myocytes and rabbit skeletal muscle fibers. J Gen Physiol, 97, 1141–1163.CrossRefPubMed

23.

Homsher, E., Lee, D. M., Morris, C., Pavlov, D., & Tobacman, L. S. (2000). Regulation of force and unloaded sliding speed in single thin filaments: effects of regulatory proteins and calcium. J Physiol, 524, 233–243.CrossRefPubMed

24.

Jarcho, J. A., McKenna, W., Pare, J. A., Solomon, S. D., Holcombe, R. F., Dickie, S., et al. (1989). Mapping a gene for familial hypertrophic cardiomyopathy to chromosome 14q1. N Engl J Med, 321, 1372–1378.PubMedCrossRef

25.

Jacques, A., Hoskins, A., Kentish, J. C., & Marston, S. B. (2008). From genotype to phenotype: a longitudinal study of a patient with hypertrophic cardiomyopathy due to a mutation in the MYBPC3 gene. J Muscle Res Cell Motility, 29, 239–246.CrossRef

26.

Javadpour, M. M., Tardiff, J. C., Pinz, I., & Ingwall, J. S. (2003). Decreased energetics in murine hearts bearing the R92Q mutation in cardiac troponin T. J Clin Invest, 112, 768–775.PubMed

27.

Keller, D. I., Coirault, C., Rau, T., Cheav, T., Weyand, M., Amann, K., et al. (2004). Human homozygous R403W mutant cardiac myosin presents disproportionate enhancement of mechanical and enzymatic properties. J Mol Cell Cardiol, 36, 355–362.CrossRefPubMed

28.

Kimura, A., Harada, H., Park, J. E., Nishi, H., Satoh, M., Takahashi, M., et al. (1997). Mutations in the cardiac troponin I gene associated with hypertrophic cardiomyopathy. Nat Genet, 16, 379–382.CrossRefPubMed

29.

Knollmann, B. C., Blatt, S. A., Horton, K., de Freitas, F., Miller, T., Bell, M., et al. (2001). Inotropic stimulation induces cardiac dysfunction in transgenic mice expressing a troponin T (I79N) mutation linked to familial hypertrophic cardiomyopathy. J Biol Chem, 276, 10039–10048.CrossRefPubMed

30.

Kulikovskaya, I., McClellan, G., Levine, R., & Winegrad, S. (2003). Effect of extraction of myosin binding protein C on contractility of rat heart. Am J Physiol Heart Circ Physiol, 285, H857–H865.PubMed

31.

Landstrom, A. P., Parvatiyar, M. S., Pinto, J. R., Marquardt, M. L., Bos, J. M., Tester, D. J., et al. (2008). Molecular and functional characterization of novel hypertrophic cardiomyopathy susceptibility mutations in TNNC1-encoded troponin C. J Mol Cell Cardiol, 45(2), 281–288.CrossRefPubMed

32.

Lankford, E. B., Epstein, N. D., Fananapazir, L., & Sweeney, H. L. (1995). Abnormal contractile properties of muscle fibers expressing beta-myosin heavy chain gene mutations in patients with hypertrophic cardiomyopathy. J Clin Invest, 95, 1409–1414.CrossRefPubMed

33.

Lin, D., Bobkova, A., Homsher, E., & Tobacman, L. S. (1996). Altered cardiac troponin T in vitro function in the presence of a mutation implicated in familial hypertrophic cardiomyopathy. J Clin Invest, 97(12), 2842–8.CrossRefPubMed

34.

Lowey, S. (2002). Functional consequences of mutations in the myosin heavy chain at sites implicated in familial hypertrophic cardiomyopathy. Trends Cardiovasc Med, 12, 348–354.CrossRefPubMed

35.

Lowey, S., Lesko, M., Rovner, A. S., Hodges, A. R., White, S. L., Low, R. B., et al. (2008). Functional effects of the hypertrophic cardiomyopathy R403Q mutation are different in an alpha- or beta-myosin heavy chain backbone. J Biol Chem, 283, 20579–2089.CrossRefPubMed

36.

Marian, A. J. (2000). Pathogenesis of diverse clinical and pathological phenotypes in hypertrophic cardiomyopathy. Lancet, 355, 58–60.CrossRefPubMed

37.

Marian, A. J., & Roberts, R. (2001). The molecular genetic basis for hypertrophic cardiomyopathy. J Mol Cell Cardiol, 33(4), 655–670.CrossRefPubMed

38.

Miller, G., Maycock, J., White, E., Peckham, M., & Calaghan, S. (2003). Heterologous expression of wild-type and mutant beta-cardiac myosin changes the contractile kinetics of cultured mouse myotubes. J Physiol, 548, 167–174.CrossRefPubMed

39.

Mogensen, J., Klausen, I. C., Pedersen, A. K., Egeblad, H., Bross, P., Kruse, T. A., et al. (1999). Alpha-cardiac actin is a novel disease gene in familial hypertrophic cardiomyopathy. J Clin Invest, 103, R39–43.CrossRefPubMed

40.

Morano, I., Bletz, C., Wojciechowski, R., & Ruegg, J. C. (1991). Modulation of crossbridge kinetics by myosin isoenzymes in skinned human heart fibers. Circ Res, 68, 614–618.PubMed

41.

Morimoto, S., Yanaga, F., Minatami, R., & Ohtsuki, I. (1998). Ca²⁺-sensitizing effects of the mutations at Ile-79 and Arg-92 of troponin T in hypertrophic cardiomyopathy. Am J Physiol, 275, C200–C207.PubMed

42.

Mulieri, L. A., Barnes, W., Leavitt, B. J., Ittleman, F. P., LeWinter, M. M., Alpert, N. R., et al. (2002). Alterations of myocardial dynamic stiffness implicating abnormal crossbridge function in human mitral regurgitation heart failure. Circ Res, 90, 66–72.CrossRefPubMed

43.

Narolska, N. A., van Loon, R. B., Boontje, N. M., Zaremba, R., Penas, S. E., Russell, J., et al. (2005). Myocardial contraction is 5-fold more economical in ventricular than in atrial human tissue. Cardiovasc Res, 65, 221–229.CrossRefPubMed

44.

Palmiter, K. A., Tyska, M. J., Haeberle, J. R., Alpert, N. R., Fananapazir, L., & Warshaw, D. M. (2000). R403Q and L908V mutant beta-cardiac myosin from patients with familial hypertrophic cardiomyopathy exhibit enhanced mechanical performance at the single molecule level. J Muscle Res Cell Motil, 21, 609–620.CrossRefPubMed

45.

Pinto, J. R., Parvatiyar, M. S., Jones, M. A., Liang, J., Ackerman, M. J., & Potter, J. D. (2009). A functional and structural study of troponin C mutations related to hypertrophic cardiomyopathy. J Biol Chem, 284, 19090–19100.CrossRefPubMed

46.

Piroddi, N., Belus, A., Scellini, B., Tesi, C., Giunti, G., Cerbai, E., et al. (2007). Tension generation and relaxation in single myofibrils from human atrial and ventricular myocardium. Pflugers Arch, 454, 63–73.CrossRefPubMed

47.

Poggesi, C., Tesi, C., & Stehle, R. (2005). Sarcomeric determinants of striated muscle relaxation kinetics. Pflügers Arch, 449, 505–517.CrossRefPubMed

48.

Poetter, K., Jiang, H., Hassanzadeh, S., Master, S. R., Chang, A., Dalakas, M. C., et al. (1996). Mutations in either the essential or regulatory light chains of myosin are associated with a rare myopathy in human heart and skeletal muscle. Nat Genet, 13, 63–69.CrossRefPubMed

49.

Redwood, C., Lohmann, K., Bing, W., Esposito, G. M., Elliott, K., Abdulrazzak, H., et al. (2000). Investigation of a truncated cardiac troponin T that causes familial hypertrophic cardiomyopathy: Ca²⁺ regulatory properties of reconstituted thin filaments depend on the ratio of mutant to wild-type protein. Circ Res, 86, 1146–1152.PubMed

50.

Richard, P., Charron, P., Carrier, L., Ledeuil, C., Cheav, T., Pichereau, C., et al. (2003). Hypertrophic cardiomyopathy: distribution of disease genes, spectrum of mutations, and implications for a molecular diagnosis strategy. Circulation, 107, 2227–2232.CrossRefPubMed

51.

Robinson, P., Griffiths, P. J., Watkins, H., & Redwood, C. S. (2007). Dilated and hypertrophic cardiomyopathy mutations in troponin and alpha-tropomyosin have opposing effects on the calcium affinity of cardiac thin filaments. Circ Res, 101, 1266–1273.CrossRefPubMed

52.

Robinson, P., Mirza, M., Knott, A., Abdulrazzak, H., Willott, R., Marston, S., et al. (2002). Alterations in thin filament regulation induced by a human cardiac troponin T mutant that causes dilated cardiomyopathy are distinct from those induced by troponin T mutants that cause hypertrophic cardiomyopathy. J Biol Chem, 277, 40710–40716.CrossRefPubMed

53.

Roopnarine, O., & Leinwand, L. A. (1998). Functional analysis of myosin mutations that cause familial hypertrophic cardiomyopathy. Biophys J, 75, 3023–3030.CrossRefPubMed

54.

Sachs, F. (1999). Practical limits on the maximal speed of solution exchange for patch clamp experiments. Biophys J, 1999(77), 682–690.CrossRef

55.

Sata, M., & Ikebe, M. (1996). Functional analysis of the mutations in the human cardiac beta-myosin that are responsible for familial hypertrophic cardiomyopathy. Implication for the clinical outcome. J Clin Invest, 98, 2866–2873.CrossRefPubMed

56.

Satoh, M., Takahashi, M., Sakamoto, T., Hiroe, M., Marumo, F., & Kimura, A. (1999). Structural analysis of the titin gene in hypertrophic cardiomyopathy: identification of a novel disease gene. Biochem Biophys Res Commun, 262, 411–417.CrossRefPubMed

57.

Seidman, J. G., & Seidman, C. (2001). The genetic basis for cardiomyopathy: from mutation identification to mechanistic paradigms. Cell, 104, 557–567.CrossRefPubMed

58.

Spindler, M., Saupe, K. W., Christe, M. E., Sweeney, H. L., Seidman, C. E., Seidman, J. G., et al. (1998). Diastolic dysfunction and altered energetics in the alphaMHC403/+ mouse model of familial hypertrophic cardiomyopathy. J Clin Invest, 101, 1775–1783.CrossRefPubMed

59.

Stehle, R., Solzin, J., Iorga, B., & Poggesi, C. (2009). Insights into the kinetics of Ca2+-regulated contraction and relaxation from myofibril studies. Pflügers Arch, 458, 337–357.CrossRefPubMed

60.

Sweeney, H. L., Feng, H. S., Yang, Z., & Watkins, H. (1998). Functional analyses of troponin T mutations that cause hypertrophic cardiomyopathy: insights into disease pathogenesis and troponin function. Proc Natl Acad Sci USA, 95, 14406–14410.CrossRefPubMed

61.

Sweeney, H. L., Straceski, A. J., Leinwand, L. A., Tikunov, B. A., & Faust, L. (1994). Heterologous expression of a cardiomyopathic myosin that is defective in its actin interaction. J Biol Chem, 269, 1603–1605.PubMed

62.

Tardiff, J. C., Hewett, T. E., Palmer, B. M., Olsson, C., Factor, S. M., Moore, R. L., et al. (1999). Cardiac troponin T mutations result in allele-specific phenotypes in a mouse model for hypertrophic cardiomyopathy. J Clin Invest, 104, 469–481.CrossRefPubMed

63.

Tesi, C., Colomo, F., Nencini, S., Piroddi, N., & Poggesi, C. (2000). The effect of inorganic phosphate on force generation in single myofibrils from rabbit skeletal muscle. Biophys J, 78, 3081–3092.CrossRefPubMed

64.

Tesi, C., Piroddi, N., Colomo, F., & Poggesi, C. (2002). Relaxation kinetics following sudden Ca²⁺ reduction in single myofibrils from skeletal muscle. Biophys J, 83, 2142–2151.CrossRefPubMed

65.

Thierfelder, L., Watkins, H., MacRae, C., Lamas, R., McKenna, W., Vosberg, H. P., et al. (1994). Alpha-tropomyosin and cardiac troponin T mutations cause familial hypertrophic cardiomyopathy: a disease of the sarcomere. Cell, 77, 701–712.CrossRefPubMed

66.

Tyska, M. J., Hayes, E., Giewat, M., Seidman, C. E., Seidman, J. G., & Warshaw, D. M. (2000). Single molecule mechanics of R403Q cardiac myosin isolated from the mouse model of familial hypertrophic cardiomyopathy. CircRes, 86, 737–744.

67.

van der Velden, J., Klein, L. J., Zaremba, R., Boontje, N. M., Huybregts, M. A., Stooker, W., et al. (2001). Effects of calcium, inorganic phosphate, and pH on isometric force in single skinned cardiomyocytes from donor and failing human hearts. Circulation, 104, 1140–1146.CrossRef

68.

van Dijk, S. J., Dooijes, D., dos Remedios, C., Michels, M., Lamers, J. M., Winegrad, S., et al. (2009). Cardiac myosin-binding protein C mutations and hypertrophic cardiomyopathy: haploin sufficiency, deranged phosphorylation, and cardiomyocyte dysfunction. Circulation, 119(11), 1473–1483.CrossRefPubMed

69.

Vignier, N., Schlossarek, S., Fraysse, B., Mearini, G., Krämer, E., Pointu, H., et al. (2009). Nonsense-mediated mRNA decay and ubiquitin-proteasome system regulate cardiac myosin-binding protein C mutant levels in cardiomyopathic mice. Circ Res, 105, 239–248.CrossRefPubMed

70.

Watkins, H., Conner, D., Thierfelder, L., Jarcho, J. A., MacRae, C., McKenna, W. J., et al. (1995). Mutations in the cardiac myosin binding protein-C gene on chromosome 11 cause familial hypertrophic cardiomyopathy. Nat Genet, 11, 434–437.CrossRefPubMed

71.

Wolff, M. R., Buck, S. H., Stoker, S. W., Greaser, M. L., & Mentzer, R. M. (1996). Myofibrillar calcium sensitivity of isometric tension is increased in human dilated cardiomyopathies: role of altered beta-adrenergically mediated protein phosphorylation. J Clin Invest, 98, 167–176.CrossRefPubMed

72.

Yamashita, H., Tyska, M. J., Warshaw, D. M., Lowey, S., & Trybus, K. M. (2000). Functional consequences of mutations in the smooth muscle myosin heavy chain at sites implicated in familial hypertrophic cardiomyopathy. J Biol Chem, 275, 28045–28052.PubMed

Title: Mechanical and Energetic Consequences of HCM-Causing Mutations
Authors: Cecilia Ferrantini
Alexandra Belus
Nicoletta Piroddi
Beatrice Scellini
Chiara Tesi
Corrado Poggesi
Publication date: 01-12-2009
Publisher: Springer US
Published in: Journal of Cardiovascular Translational Research / Issue 4/2009
Print ISSN: 1937-5387
Electronic ISSN: 1937-5395
DOI: https://doi.org/10.1007/s12265-009-9131-8

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

At a glance: The STEP trials

Springer Medicine

Mechanical and Energetic Consequences of HCM-Causing Mutations

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2009

A Good Idea: A Physician’s Perspective on Genetic Counseling for Hypertrophic Cardiomyopathy

Evolving Anatomic, Functional, and Molecular Imaging in the Early Detection and Prognosis of Hypertrophic Cardiomyopathy

Hypertrophic Cardiomyopathy: The Early Years

Looking for Hypertrophic Cardiomyopathy in the Community: Why Is It Important?

Hypertrophic Cardiomyopathy: Preclinical and Early Phenotype

Research.... Beyond Experiments!

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page